Quantum BioPharma (NASDAQ:QNTM) has successfully completed oral dosing in both its 180-day repeated-dose toxicity and toxicokinetic studies for Lucid-21-302, its lead candidate for the treatment of multiple sclerosis (MS).
The completion of these chronic safety studies marks a pivotal transition for the "Lucid-MS" program, providing the foundational data required for an Investigational New Drug (IND) application with the U.S. FDA.
Unlike existing MS therapies that primarily focus on immunosuppression to reduce inflammation, Lucid-MS is a patented new chemical entity designed as a neuroprotective agent.
Preclinical models have demonstrated the drug’s potential to inhibit demyelination and actually promote myelin repair—the "holy grail" of MS treatment that could potentially reverse existing nerve damage rather than just slowing disease progression.
The data from these 180-day studies are intended to inform the final design of a planned Phase 2 clinical trial.
By establishing the long-term safety and metabolic profile of the compound in these chronic models, Quantum BioPharma can now refine the dosing schedules and safety monitoring protocols for its upcoming study in MS patients.